Marksans Pharma Ltd.

==> picture [205 x 69] intentionally omitted <==

January 27, 2026

BSE Limited National Stock Exchange of India Limited Corporate Relation Department Listing Department Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block - G Dalal Street Bandra-Kurla Complex Mumbai – 400001 Bandra (East), Mumbai - 400051 Scrip Code: 524404 Symbol: MARKSANS

Sub.: Intimation regarding incorporation of two new wholly owned subsidiary companies.

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI LODR Regulations, this is to inform you that Marksans Pharma Limited has formed and incorporated the following two new wholly owned subsidiary companies:

Marksans Pharma (Europe) Limited in Ireland.
Marksans (Canada) Inc. in Canada.

The relevant details as required under SEBI LODR Regulations are enclosed as Annexure – A.

Thanking you.

Yours faithfully For Marksans Pharma Limited

Digitally signed H by H PANIGRAHI PANIGRAHI Date: 2026.01.27 13:00:44 +05'30'

Harshavardhan Panigrahi Company Secretary

==> picture [6 x 75] intentionally omitted <==

11[th] Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai - 400 053 Tel.: +91 22 4001 2000 E-mail: [email protected]

www.marksanspharma.com

==> picture [195 x 62] intentionally omitted <==

Annexure A

Sr.No.	Particulars	Marksans Pharma (Europe)Limited	Marksans (Canada) Inc.
1	Name of the target entity, details in briefsuch as size, turnover etc.;	The name of the wholly ownedsubsidiary is Marksans Pharma(Europe) Limited, incorporatedin Ireland.Size/Turnover: Not applicablebeing a newly incorporatedcompany.	The name of the whollyownedsubsidiaryisMarksans (Canada) Inc.,incorporated in Canada.Size/Turnover:Notapplicable being a newlyincorporated company.
2	Whether the acquisition would fallwithin related party transaction(s) andwhether the promoter/ promoter group/group companies have any interest inthe entity being acquired? If yes, natureof interest and details thereof andwhether the same is done at “arm’slength”;	Not Applicable	Not Applicable
3	Industry to which the entity beingacquired belongs;	Pharmaceutical	Pharmaceutical
4	Objects and impact of acquisition(including but not limited to, disclosureof reasons for acquisition of targetentity, if its business is outside the mainline of business of the listed entity);	The wholly owned subsidiary hasbeen incorporated in Ireland forthe purpose of carrying on thebusinessofpharmaceuticalproducts.	Thewhollyownedsubsidiaryhasbeenincorporated in Canada forthe purpose of carrying onthebusinessofpharmaceuticalproducts.
5	Brief details of any governmental orregulatory approvals required for theacquisition;	Not Applicable	Not Applicable
6	Indicative time period for completion ofthe acquisition;	Not Applicable	Not Applicable
7	Consideration-whethercashconsideration or share swap or anyother form and details of the same;	Not Applicable	Not Applicable
8	Cost of acquisition and/or the price atwhich the shares are acquired;	Not Applicable	Not Applicable
9	Percentage of shareholding / controlacquired and / or number of sharesacquired;	The Company is a wholly ownedsubsidiary.	The Company is a whollyowned subsidiary.
10	Brief background about the entityacquired in terms of products/line ofbusinessacquired,dateofincorporation, history of last 3 yearsturnover, country in which the acquiredentity has presence and any othersignificant information(inbrief);	HistoryandTurnover:NotApplicable,beinganewlyincorporated company.	History and Turnover: NotApplicable, being a newlyincorporated company.

==> picture [5 x 74] intentionally omitted <==